Switch 2
Switch 2, licence 80064905: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Switch
- Licence holder
- Max International LLC
- NPN or DIN-HM
- 80064905
- Status
- Active licence
- Licence date
- 2 November 2015
- Revision date
- 12 April 2019
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine D: up to 25 µg a day according to the dosing instructions published by Health Canada (6 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 15 mg a day according to the dosing instructions published by Health Canada (6 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Vitamine B6: up to 15 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (12 mg a day). Le repère de l'EFSA porte sur l'apport total d'une journée, alimentation et compléments.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| L-Leucine Source : L-Leucine | 8.5 milligramme | Not calculated |
| Vitamine D Source : Ergocalciférol | 4.17 microgrammes | Not calculated |
| Vitamine D Source : Ergocalciférol | 166.67 UI | 25.0005 µg |
| Thiamine Source : Chlorhydrate de thiamine | 0.5 milligramme | 3,000 µg |
| Vitamine B6 Source : Chlorhydrate de pyridoxine | 2.5 milligramme | 15,000 µg |
| Vitamine B12 Source : Méthylcobalamine | 8.0 microgrammes | Not calculated |
| (S)-N5-Carbamoylornithine Source : Malate de citrulline | 8.5 milligramme | Not calculated |
| Potassium Source : Citrate de potassium | 3.6 milligramme | 21,600 µg |
| Acide DL-alpha-lipoïque Source : Acide DL-alpha-lipoÏque | 200.0 milligramme | Not calculated |
| Panax quinquefolius Source : Panax quinquefolius root Extract : Matériel brut sec Extraction ratio : 2:1 Dry plant equivalent : 17 milligramme Potency : 5.0 % Ginsenosides | 8.5 milligramme | Not calculated |
| D-Ribose-L-cystéine Source : D-Ribose-L-cystéine Potency : 44.7 % L-Cysteine | 3.0 milligramme | Not calculated |
| D-Ribose-L-cystéine Source : D-Ribose-L-cystéine Potency : 55.3 % Ribose | Not specified | Not calculated |
| D-Ribose-L-cystéine Source : D-Ribose-L-cystéine Potency : 1.44 milligramme L-Cysteine | Not specified | Not calculated |
| D-Ribose-L-cystéine Source : D-Ribose-L-cystéine Potency : 1.78 milligramme Ribose | Not specified | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Cellulose microcristalline, Hypromellose, Maltodextrine, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Capsule | 3.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
To be used with a program of reduced intake of dietary calories and increased physical activity (if possible) to help in weight management. Assists in weight management when used with a program of reduced intake of dietary calories and increased physical activity (if possible) to help in weight management. Helps the body to metabolize carbohydrates, proteins and fats. Helps to promote healthy glucose metabolism. Helps to prevent vitamin D, thiamine, vitamin B6, vitamin B12, and pantothenic acid deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80064905
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2019. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.